Clinical Efficacy of Tranexamic Acid and ε-Aminocaproic Acid in Reducing Blood Loss Following Total Knee Replacement

Completed · Phase 4

Conditions studied: Osteoarthritis

In brief

Tranexamic acid (TXA) and ε-aminocaproic acid (EACA) are two drugs shown to limit blood loss following major surgery, from cardiac to orthopedic procedures. Yet compared to tranexamic acid (TXA), research on the clinical impact of ε-aminocaproic acid (EACA) in total knee arthroplasty (TKA) is limited. The primary aim of this study is to determine whether TXA and EACA provide similar blood decreasing effects following TKA or whether one drug provides a superior effect over the other in reducing patients' blood loss.

Key facts

Study ID

NCT01873768

Run by

Miller Orthopedic Specialists

People needed

194

Starts

2014-01-01

Expected to finish

2015-12-01

Last updated by the study team

2016-03-21

Who can join

Age: 18 and older, up to 90. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Persons aged 18 - 90 years who are scheduled to undergo a unilateral total knee replacement surgery

You may not qualify if…

• Non-English speaking individuals
• Individuals with a history of deep vein thrombosis or pulmonary embolism within one year
• Individuals with a history of coagulopathy
• Heart stent within one year
• Pre-operative autologous blood donation
• Unwilling or unable to take Coumadin for deep vein thrombosis (DVT) prophylaxis
• Received nonsteroidal anti-inflammatory drug (NSAID) or platelet antiaggregant treatment within five days prior to surgery
• Pre-operative creatinine greater than 1.5mg/dL

Where it is running

• Miller Orthopedic Specialists — Council Bluffs, Iowa, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.